Heidi Raises $340M Across Series C and Growth Capital

Healthcare AI has two expensive jobs: build a product clinicians trust, then carry it through the procurement, integration, training, and governance required to make it useful inside a health system. Heidi is financing those jobs with two different pools of capital.

The Melbourne-founded company announced $340M in new funding on September 22, 2026. Blackbird led a $100M Series C, with Phoenix Court, Point72 Private Investments, and Headline participating, while General Catalyst's Customer Value Fund supplied a separate $240M growth investment. Heidi said the equity round valued the company at $900M.

The distinction inside that $340M matters. One pool backs the company through equity; the other is designed to expand go-to-market capacity. Together they give Heidi more room to build clinical AI and more capital to move it through the institutional handoffs that determine whether healthcare software becomes routine care infrastructure.

What Heidi Raised

The $100M Series C is the equity component of the announcement. It nearly doubles the $465M valuation reported when Point72 Private Investments led Heidi's $65M Series B in October 2025. Heidi now reports $436.6M in cumulative funding, which combines the $340M announced in September 2026 with the $96.6M it had previously disclosed.

The remaining $240M comes from General Catalyst's Customer Value Fund. General Catalyst describes its broader model as pre-funding sales and marketing against the customer value produced by the cohorts that spending helps acquire, with the investor's return capped. Independent reporting says Heidi's facility carries no equity or warrants, but the full Heidi-specific contract is private, so its pricing, eligibility rules, reporting obligations, and downside mechanics should not be inferred from the public fund description.

That capital accounting keeps the financing honest. Heidi has not raised a $340M Series C, and the CVF portion is neither another equity check nor a conventional bank loan with publicly disclosed terms. It is growth capital aimed at the commercial work of acquiring and expanding customers.

Why the Split Structure Matters

Clinical AI companies can earn bottom-up adoption from individual clinicians long before an enterprise deployment becomes repeatable. A health system still has to evaluate security, privacy, clinical governance, EHR integration, training, implementation, procurement, and budget ownership. Each step belongs to a different team, and every handoff can slow or reshape the rollout.

Heidi's financing separates some of that work by risk. Equity can support product, engineering, regulatory work, and market expansion where returns are uncertain and long-dated. The Customer Value capital is associated with go-to-market activity, where General Catalyst's model assumes customer acquisition can be measured against the value created by funded cohorts.

The structure also raises a sharper operating question than the headline amount. More commercial capacity can open more health-system conversations, but the durable economics still depend on implementation speed, clinician activation, retention, expansion, support requirements, and the quality of care workflows after the first enthusiasm fades. Heidi has not publicly disclosed those cohort economics.

From Clinical Notes to Supervised Action

Dr. Thomas Kelly, Waleed Mussa, and Yu Liu founded Heidi in Melbourne in 2021. Thomas Kelly serves as CEO and Yu Liu as CTO; current company pages disagree on whether Mussa's operating title is CFO or COO, so the stable public description is co-founder. The team's first wedge was ambient documentation that listens during a consultation and produces a structured note for clinician review.

Heidi now describes the product as an AI Care Partner. Its portfolio includes Scribe, Evidence for clinical research support, Remote for audio capture, Dictate, forms, tasks, medical coding support, patient communications, and EHR integrations. The company says its next phase will move beyond documentation into supervised clinical actions while leaving medical judgment with qualified clinicians.

The scale claims are substantial and remain company-reported. Heidi says the platform supports 2.8M patient visits each week across 190 countries and 110 languages, has supported more than 175M visits and 67M clinical hours in total, and grew annual recurring revenue from $1M to $50M in two years, reaching that level in April 2026. Independent coverage corroborates that these are the figures Heidi disclosed, but the sources reviewed do not provide an external audit of usage, revenue, time saved, margins, or clinical outcomes.

The Distribution Test in Healthcare AI

Heidi names NHS Midlands, Metro South Health, Health New Zealand, and Beth Israel Lahey Health among the public systems and major networks using its platform. The company also opened Toronto as its North American headquarters and announced a C$25.4M Canadian investment spanning research, partnerships, engineering, clinical roles, and commercial hiring.

Those deployments make distribution more concrete than a generic expansion plan. Each system brings its own documentation habits, privacy boundaries, EHR configuration, governance process, and clinical culture. Heidi's product has to become configurable enough to travel without turning every new customer into a bespoke services project.

The company's move toward supervised actions raises the burden further. Writing a note is one workflow; initiating or coordinating work around a patient visit creates new questions about permissions, review, auditability, failure handling, and regulatory treatment. Heidi says clinicians will retain judgment, but the quality of that human-machine handoff will be tested market by market.

What the Funding Changes

The Series C gives Heidi more capacity to develop the product, build evidence, meet regulatory requirements, and hire. The Customer Value investment gives it a larger dedicated pool for the commercial machinery around health-system adoption. That combination could let the company expand without asking equity alone to finance every new deployment.

Capital cannot complete the institutional handoff by itself. The record that matters next will accumulate through implementation timelines, active clinician use, renewal and expansion, support intensity, and the evidence health systems require before supervised clinical AI takes on more of the workday. Heidi has financed a larger attempt at that record, and the outcome will be written inside the systems it is trying to change.